Important MS Medications to Remain Affordable for Australians
The Australian government has announced that two essential medications for Multiple Sclerosis (MS), Ocrevus and Kesimpta, will continue to be listed on the Pharmaceutical Benefits Scheme (PBS). This decision ensures that these high-efficacy treatments remain affordable and accessible for patients across the country.
MS Australia, the national peak body for the disease, has welcomed the announcement. These medications are classified as disease-modifying therapies, which help manage the condition by slowing down its progression. For many people living with MS, these drugs are vital for maintaining their quality of life and health.
By keeping these treatments on the PBS, the government is subsidizing the high cost of the drugs. Without this support, many patients would struggle to pay the full price for their ongoing care. This move is seen as a significant commitment to supporting Australians who are managing chronic health conditions.
This decision provides long-term certainty for patients and their families. As these medications are often used as first-line treatments, their continued availability on the PBS allows doctors to prescribe them early, which is crucial for managing the long-term effects of MS. The government's support ensures that financial barriers do not prevent patients from receiving the best possible medical care.